Literature DB >> 18720213

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.

Chadi Al-Nawakil, Jerome Tamburini, Valerie Bardet, Nicolas Chapuis, Edward Bourry, Christian Roux, Sophie Park, Sylvain Choquet, François Dreyfus, Didier Bouscary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18720213     DOI： 10.1080/10428190802290660

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  Primary plasma cell leukemia followed by testicular plasmacytoma.

Authors:  Caterina Giovanna Valentini; Valentina Bozzoli; Luana Fianchi; Maria Teresa Voso; Gianluigi Di Paolantonio; Marianna Criscuolo; Giuseppe Leone; Luigi Maria Larocca; Livio Pagano
Journal:  Int J Hematol       Date:  2011-01-13       Impact factor: 2.490

2.  A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Mutsumi Wakabayashi; Keiji Sugimoto; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

Review 4.  Plasma cell leukemia.

Authors:  Flavio Albarracin; Rafael Fonseca
Journal:  Blood Rev       Date:  2011-02-03       Impact factor: 8.250

Review 5.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 6.  Primary Plasma Cell Leukemia: Identity Card 2016.

Authors:  Pellegrino Musto; Vittorio Simeon; Katia Todoerti; Antonino Neri
Journal:  Curr Treat Options Oncol       Date:  2016-04

Review 7.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

8.  Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.

Authors:  A Mahindra; M E Kalaycio; J Vela-Ojeda; D H Vesole; M-J Zhang; P Li; J R Berenson; J M Bird; A Dispenzieri; J L Gajewski; R P Gale; L Holmberg; S Kumar; R A Kyle; H M Lazarus; S Lonial; J Mikhael; G A Milone; R Munker; R Nath; S Saccaro; L Bik To; D T Vogl; B Wirk; P Hari
Journal:  Leukemia       Date:  2011-11-01       Impact factor: 11.528

9.  Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.

Authors:  Steven M Chan; Tracy George; Athena M Cherry; Bruno C Medeiros
Journal:  Cases J       Date:  2009-02-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.